Advertisement
Screener

Standard BioTools Inc. (LAB) Payments to Acquire Investments

1.7 / 5 stars · 27/80 Roast Me

Standard BioTools Inc. Payments to Acquire Investments

Standard BioTools Inc. (LAB) reported Payments to Acquire Investments of $137.30 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireInvestments · last filed 2022-11-09

  • Standard BioTools Inc. payments to acquire investments for the quarter ending 2022-09-30 was $0.00.
  • Standard BioTools Inc. payments to acquire investments for the quarter ending 2021-12-31 was $0.00.
  • Standard BioTools Inc. payments to acquire investments for the quarter ending 2021-09-30 was $0.00.
  • Standard BioTools Inc. payments to acquire investments for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
  • Standard BioTools Inc. payments to acquire investments for fiscal 2021 was $0.00.
  • Standard BioTools Inc. payments to acquire investments for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
  • Standard BioTools Inc. payments to acquire investments for fiscal 2019 was $62.37M, a 4201.38% increase from fiscal 2018.
  • Standard BioTools Inc. payments to acquire investments for fiscal 2018 was $1.45M, a 76.90% decline from fiscal 2017.
Period endPayments to Acquire Investments 3 monthPayments to Acquire Investments 6 monthPayments to Acquire Investments 9 monthPayments to Acquire Investments 12 month
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$137.30M
10-Q · filed 2022-11-09
2022-06-30$137.30M
10-Q · filed 2022-08-09
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$0.00
derived: sum of 2 quarters · filed 2022-11-09
$0.00
10-K · filed 2022-03-08
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$0.00
10-Q · filed 2022-11-09
2021-06-30$0.00
10-Q · filed 2022-08-09
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$0.00
derived: sum of 2 quarters · filed 2022-03-08
$0.00
derived: sum of 3 quarters · filed 2022-03-08
$0.00
10-K · filed 2022-03-08
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$0.00
derived: sum of 2 quarters · filed 2020-11-09
$0.00
10-Q · filed 2020-11-09
$9.65M
derived: sum of 4 quarters · filed 2022-03-08
2020-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$0.00
10-Q · filed 2020-08-07
$9.65M
derived: sum of 3 quarters · filed 2022-03-08
$17.76M
derived: sum of 4 quarters · filed 2022-03-08
2020-03-31$0.00
10-Q · filed 2020-05-11
$9.65M
derived: sum of 2 quarters · filed 2022-03-08
$17.76M
derived: sum of 3 quarters · filed 2022-03-08
$52.88M
derived: sum of 4 quarters · filed 2022-03-08
2019-12-31$9.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$17.76M
derived: sum of 2 quarters · filed 2022-03-08
$52.88M
derived: sum of 3 quarters · filed 2022-03-08
$62.37M
10-K · filed 2022-03-08
2019-09-30$8.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$43.23M
derived: sum of 2 quarters · filed 2020-11-09
$52.72M
10-Q · filed 2020-11-09
$52.72M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$35.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$44.61M
10-Q · filed 2020-08-07
$44.61M
derived: sum of 3 quarters · filed 2021-02-25
$44.61M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$9.49M
10-Q · filed 2020-05-11
$9.49M
derived: sum of 2 quarters · filed 2021-02-25
$9.49M
derived: sum of 3 quarters · filed 2021-02-25
$10.76M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$1.00K
derived: sum of 2 quarters · filed 2021-02-25
$1.26M
derived: sum of 3 quarters · filed 2021-02-25
$1.45M
10-K · filed 2021-02-25
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$1.26M
derived: sum of 2 quarters · filed 2019-11-08
$1.45M
10-Q · filed 2019-11-08
$6.28M
derived: sum of 4 quarters · filed 2020-02-27
2018-06-30$1.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
$1.45M
10-Q · filed 2019-08-07
$6.28M
derived: sum of 3 quarters · filed 2020-02-27
$6.28M
derived: sum of 4 quarters · filed 2020-02-27
2018-03-31$186.00K
10-Q · filed 2019-05-07
$5.01M
derived: sum of 2 quarters · filed 2020-02-27
$5.01M
derived: sum of 3 quarters · filed 2020-02-27
$5.28M
derived: sum of 4 quarters · filed 2020-02-27
2017-12-31$4.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$4.82M
derived: sum of 2 quarters · filed 2020-02-27
$5.09M
derived: sum of 3 quarters · filed 2020-02-27
$6.28M
10-K · filed 2020-02-27
2017-09-30-$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
$267.00K
derived: sum of 2 quarters · filed 2018-11-06
$1.45M
10-Q · filed 2018-11-06
$1.48M
derived: sum of 4 quarters · filed 2019-03-18
2017-06-30$269.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
$1.45M
10-Q · filed 2018-08-08
$1.48M
derived: sum of 3 quarters · filed 2019-03-18
$5.49M
derived: sum of 4 quarters · filed 2019-03-18
2017-03-31$1.18M
10-Q · filed 2018-05-08
$1.21M
derived: sum of 2 quarters · filed 2019-03-18
$5.22M
derived: sum of 3 quarters · filed 2019-03-18
$31.26M
derived: sum of 4 quarters · filed 2019-03-18
2016-12-31$30.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$4.04M
derived: sum of 2 quarters · filed 2019-03-18
$30.08M
derived: sum of 3 quarters · filed 2019-03-18
$38.59M
10-K · filed 2019-03-18
2016-09-30$4.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$30.05M
derived: sum of 2 quarters · filed 2017-11-07
$38.56M
10-Q · filed 2017-11-07
$51.83M
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30$26.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
$34.56M
10-Q · filed 2017-08-08
$47.83M
derived: sum of 3 quarters · filed 2018-03-08
$67.80M
derived: sum of 4 quarters · filed 2018-03-08
2016-03-31$8.51M
10-Q · filed 2017-05-09
$21.78M
derived: sum of 2 quarters · filed 2018-03-08
$41.76M
derived: sum of 3 quarters · filed 2018-03-08
$75.49M
derived: sum of 4 quarters · filed 2018-03-08
2015-12-31$13.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$33.24M
derived: sum of 2 quarters · filed 2018-03-08
$66.97M
derived: sum of 3 quarters · filed 2018-03-08
$66.97M
10-K · filed 2018-03-08
2015-09-30$19.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
$53.70M
derived: sum of 2 quarters · filed 2016-11-09
$53.70M
10-Q · filed 2016-11-09
$79.68M
derived: sum of 4 quarters · filed 2017-03-03
2015-06-30$33.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
$33.73M
10-Q · filed 2016-08-09
$59.70M
derived: sum of 3 quarters · filed 2017-03-03
$79.58M
derived: sum of 4 quarters · filed 2017-03-03
2015-03-31$0.00
10-Q · filed 2016-05-09
$25.97M
derived: sum of 2 quarters · filed 2017-03-03
$45.85M
derived: sum of 3 quarters · filed 2017-03-03
$117.64M
derived: sum of 4 quarters · filed 2017-03-03
2014-12-31$25.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03
$45.85M
derived: sum of 2 quarters · filed 2017-03-03
$117.64M
derived: sum of 3 quarters · filed 2017-03-03
$132.64M
10-K · filed 2017-03-03
2014-09-30$19.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$91.67M
derived: sum of 2 quarters · filed 2015-11-09
$106.67M
10-Q · filed 2015-11-09
$109.28M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$71.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
$86.79M
10-Q · filed 2015-08-10
$89.40M
derived: sum of 3 quarters · filed 2016-02-29
$105.61M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$15.00M
10-Q · filed 2015-05-11
$17.61M
derived: sum of 2 quarters · filed 2016-02-29
$33.82M
derived: sum of 3 quarters · filed 2016-02-29
$67.03M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$2.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$18.82M
derived: sum of 2 quarters · filed 2016-02-29
$52.02M
derived: sum of 3 quarters · filed 2016-02-29
$59.44M
10-K · filed 2016-02-29
2013-09-30$16.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
$49.42M
derived: sum of 2 quarters · filed 2014-11-06
$56.83M
10-Q · filed 2014-11-06
$64.51M
derived: sum of 4 quarters · filed 2015-02-26
2013-06-30$33.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04
$40.62M
10-Q · filed 2014-08-04
$48.30M
derived: sum of 3 quarters · filed 2015-02-26
$53.64M
derived: sum of 4 quarters · filed 2015-02-26
2013-03-31$7.41M
10-Q · filed 2014-05-12
$15.09M
derived: sum of 2 quarters · filed 2015-02-26
$20.43M
derived: sum of 3 quarters · filed 2015-02-26
$23.41M
derived: sum of 4 quarters · filed 2015-02-26
2012-12-31$7.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26
$13.02M
derived: sum of 2 quarters · filed 2015-02-26
$15.99M
derived: sum of 3 quarters · filed 2015-02-26
$35.38M
10-K · filed 2015-02-26
2012-09-30$5.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
$8.31M
derived: sum of 2 quarters · filed 2013-11-07
$27.70M
10-Q · filed 2013-11-07
$38.54M
derived: sum of 4 quarters · filed 2014-03-12
2012-06-30$2.97M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$22.36M
10-Q · filed 2013-08-07
$33.20M
derived: sum of 3 quarters · filed 2014-03-12
$36.03M
derived: sum of 4 quarters · filed 2014-03-12
2012-03-31$19.39M
10-Q · filed 2013-05-09
$30.23M
derived: sum of 2 quarters · filed 2014-03-12
$33.06M
derived: sum of 3 quarters · filed 2014-03-12
$68.90M
derived: sum of 4 quarters · filed 2014-03-12
2011-12-31$10.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12
$13.67M
derived: sum of 2 quarters · filed 2014-03-12
$49.51M
derived: sum of 3 quarters · filed 2014-03-12
$71.38M
10-K · filed 2014-03-12
2011-09-30$2.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
$38.67M
derived: sum of 2 quarters · filed 2012-11-09
$60.54M
10-Q · filed 2012-11-09
2011-06-30$35.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14
$57.71M
10-Q · filed 2012-08-14
2011-03-31$21.87M
10-Q · filed 2012-05-15
2010-12-31$0.00
10-K · filed 2013-03-12
2009-12-31$0.00
10-K · filed 2012-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01